| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
From the Departments of Pathology,*
Medical
Biochemistry,
and
Medicine
(Liver Unit), University of
Calgary, Calgary, Canada
A rat model of common bile duct ligation (BDL)-induced hepatic fibrosis was used to assess the expression and activities of collagen-degrading proteinases and their inhibitors during the progression of fibrosis. Expression of four members of the matrix metalloproteinase (MMP) family (MMP-2/gelatinase A, MMP-3, MMP-9/gelatinase B, and MMP-13) and three tissue inhibitors of metalloproteinases-1, -2, and -3 (TIMP-1, TIMP-2, and TIMP-3) were evaluated by Northern blot analysis of RNA from liver tissue isolated at 0, 2, 5, 10, 20, and 30 days after either a BDL or sham operation. In addition, we analyzed free gelatinase and TIMP activities by zymography and reverse zymography, respectively. We found that the proteolytic activities of MMP-2 and MMP-9 increased by 2 days after ligation, reached maximal levels at day 10, and remained high through the study period, whereas the gelatinolytic activities in plasma were unchanged. The increase in gelatinase activities was accompanied by an increase in the TIMP mRNA transcripts. TIMP-1 transcripts appeared at day 2, increased until day 10, and remained elevated throughout the study period. TIMP-2 and TIMP-3 transcripts become detectable on day 10 and remained stable afterwards. No corresponding increase in TIMP protein activity was detected by reverse zymography. This appears to result from the formation of TIMP/MMP complexes. These findings indicate a likely surplus in the BDL model of fibrosis of free gelatinases as compared with the TIMPs. Thus, excessive TIMP production is not a sufficient explanation for the observed extracellular matrix accumulation, but complex changes in the local MMP/TIMP balance may underlie the pathomechanisms of fibrosis.
This article has been cited by other articles:
 |
|
 |
|
  Y.-P. Han, C. Yan, L. Zhou, L. Qin, and H. Tsukamoto A Matrix Metalloproteinase-9 Activation Cascade by Hepatic Stellate Cells in Trans-differentiation in the Three-dimensional Extracellular Matrix J. Biol. Chem., April 27, 2007; 282(17): 12928 - 12939. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M R Ebrahimkhani, S Kiani, F Oakley, T Kendall, A Shariftabrizi, S M Tavangar, L Moezi, S Payabvash, A Karoon, H Hoseininik, et al. Naltrexone, an opioid receptor antagonist, attenuates liver fibrosis in bile duct ligated rats Gut, November 1, 2006; 55(11): 1606 - 1616. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Plumb, S McQuaid, A K Cross, J Surr, G Haddock, R A. Bunning, and M N Woodroofe Upregulation of ADAM-17 expression in active lesions in multiple sclerosis Multiple Sclerosis, August 1, 2006; 12(4): 375 - 385. [Abstract] [PDF]
|
|
|
|
|
|
Y. Popov, E. Patsenker, M. Bauer, E. Niedobitek, A. Schulze-Krebs, and D. Schuppan Halofuginone Induces Matrix Metalloproteinases in Rat Hepatic Stellate Cells via Activation of p38 and NF{kappa}B J. Biol. Chem., June 2, 2006; 281(22): 15090 - 15098. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-B. Park, J.-K. Lee, S.-J. Park, and K. D. Riew Hypertrophy of Ligamentum Flavum in Lumbar Spinal Stenosis Associated with Increased Proteinase Inhibitor Concentration J. Bone Joint Surg. Am., December 1, 2005; 87(12): 2750 - 2757. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Bourd-Boittin, D. Septier, R. Hall, M. Goldberg, and S. Menashi Immunolocalization of Enamelysin (Matrix Metalloproteinase-20) in the Forming Rat Incisor J. Histochem. Cytochem., April 1, 2004; 52(4): 437 - 445. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-P. Han, L. Zhou, J. Wang, S. Xiong, W. L. Garner, S. W. French, and H. Tsukamoto Essential Role of Matrix Metalloproteinases in Interleukin-1-induced Myofibroblastic Activation of Hepatic Stellate Cell in Collagen J. Biol. Chem., February 6, 2004; 279(6): 4820 - 4828. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Schlotzer-Schrehardt, J. Lommatzsch, M. Kuchle, A. G. P. Konstas, and G. O. H. Naumann Matrix Metalloproteinases and Their Inhibitors in Aqueous Humor of Patients with Pseudoexfoliation Syndrome/Glaucoma and Primary Open-Angle Glaucoma Invest. Ophthalmol. Vis. Sci., March 1, 2003; 44(3): 1117 - 1125. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. R. Mertens, K. Steinmann, M. A. Alfonso-Jaume, A. En-Nia, Y. Sun, and D. H. Lovett Combinatorial Interactions of p53, Activating Protein-2, and YB-1 with a Single Enhancer Element Regulate Gelatinase A Expression in Neoplastic Cells J. Biol. Chem., July 5, 2002; 277(28): 24875 - 24882. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Perez, A. Suarez, J. A. Gomez-Capilla, F. Sanchez-Medina, and A. Gil Dietary Nucleotide Supplementation Reduces Thioacetamide-Induced Liver Fibrosis in Rats J. Nutr., April 1, 2002; 132(4): 652 - 657. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. P. Arthur Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis Am J Physiol Gastrointest Liver Physiol, August 1, 2000; 279(2): G245 - G249. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C S SETHI, T A BAILEY, P J LUTHERT, and N H V CHONG Matrix metalloproteinase biology applied to vitreoretinal disorders Br. J. Ophthalmol., June 1, 2000; 84(6): 654 - 666. [Full Text]
|
|
|
|
|
|
R C BENYON and J P IREDALE Is liver fibrosis reversible? Gut, April 1, 2000; 46(4): 443 - 446. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Y. S. Oh, P. H. Larsen, C. A. Krekoski, D. R. Edwards, F. Donovan, Z. Werb, and V. W. Yong Matrix Metalloproteinase-9/Gelatinase B Is Required for Process Outgrowth by Oligodendrocytes J. Neurosci., October 1, 1999; 19(19): 8464 - 8475. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. E. Kossakowska, D. R. Edwards, C. Prusinkiewicz, M. C. Zhang, D. Guo, S. J. Urbanski, T. Grogan, L. A. Marquez, and A. Janowska-Wieczorek Interleukin-6 Regulation of Matrix Metalloproteinase (MMP-2 and MMP-9) and Tissue Inhibitor of Metalloproteinase (TIMP-1) Expression in Malignant Non-Hodgkin's Lymphomas Blood, September 15, 1999; 94(6): 2080 - 2089. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
